| Autor: |
Jacobs, Jeremy M., Stessman, Jochanan |
| Předmět: |
|
| Zdroj: |
Archives of Internal Medicine; 3/12/2012, Vol. 172 Issue 5, p403-404, 2p |
| Abstrakt: |
The authors claim that only a balanced view of high-quality data for dabigatran, a direct thrombin inhibitor, can allow an assessment needed to guide clinical decisions. It is said that the acknowledgement of the power of market forces, the responsibility in pharmaceutical research and development and the role of regulator are critical vectors that must be unified before achieving drug safety. The reasons for underreporting adverse drug events in clinical trials are said to be complex. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
